Leveraging Genetic Determinants of Prostate-Specific Antigen Levels Towards Improving Prostate Cancer Screening
- Kachuri, Linda
- Hoffmann, Thomas J
- Jiang, Yu
- Berndt, Sonja I.
- Shelley, John P.
- Schaffer, Kerry
- Machiela, Mitchell J.
- Freedman, Neal D.
- Huang, Wen-Yi
- Li, Shengchao A.
- Easterlin, Ryder
- Goodman, Phyllis J.
- Till, Cathee
- Thompson, Ian
- Lilja, Hans
- Van Den Eeden, Stephen K.
- Chanock, Stephen J.
- Haiman, Christopher A.
- Conti, David V.
- Klein, Robert J.
- Mosley, Jonathan D.
- Graff, Rebecca E.
- Witte, John S.
Publication date
December 2022
DOIAbstract
Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer PSA variation has potential to improve screening utility. We discovered 128 genome-wide significant associations (P<5×10-8) in a multi-ancestry GWAS meta-analysis of 95,768 men and developed a PSA polygenic score (PGSPSA) that explains 9.61% of constitutive PSA variation. Here we provide full GWAS summary statistics for the multi-ancestry meta-analysis and ancestry-stratified summary statistics for ~1.2 million variants used to derive a genome-wide PGSPSA
Add to ORKG